<SEC-DOCUMENT>0001654954-23-014647.txt : 20231121
<SEC-HEADER>0001654954-23-014647.hdr.sgml : 20231121
<ACCEPTANCE-DATETIME>20231121103226
ACCESSION NUMBER:		0001654954-23-014647
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231121
FILED AS OF DATE:		20231121
DATE AS OF CHANGE:		20231121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FSD Pharma Inc.
		CENTRAL INDEX KEY:			0001771885
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39152
		FILM NUMBER:		231424912

	BUSINESS ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
		BUSINESS PHONE:		(416) 854-8884

	MAIL ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>fsd_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title>fsd_6k.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Washington, D.C. 20549</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:18pt">FORM 6-K</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PURSUANT TO RULE 13a-16 OR 15d-16</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the month of November 2023</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Commission File Number: 001-39152</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><font style="font-size:18pt"><strong>FSD PHARMA INC.</strong></font></p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Registrant)</strong></p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>199 Bay St., Suite 4000</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Toronto, Ontario M5L 1A9 Canada</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(Address of Principal Executive Offices)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Form 20-F &#9746;&nbsp;&nbsp; Form 40-F &#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp; &#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp; &#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>SIGNATURES</u></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><strong><u id="del_u41f2c241-e4ef-48e0-b8dd-71fbb7771fd4"></u></strong> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>&nbsp;</td> <td colspan="2"> <p style="margin:0px 0px 0px 0in"><strong>FSD PHARMA INC.</strong></p></td> <td></td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td colspan="2">(Registrant)</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px 0px 0px 0in">Date November 21, 2023</p></td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;"> <p style="margin:0px 0px 0px 0in">/s/ Nathan Coyle</p></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px 0px 0px 0in">Nathan Coyle</p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p style="margin:0px 0px 0px 0in">Chief Financial Officer</p></td> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">2</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>EXHIBIT INDEX</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Exhibit</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Description of Exhibit</strong><strong></strong></p></td></tr> <tr style="height:15px"> <td></td> <td colspan="2"></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="fsd_ex991.htm">99.1</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="fsd_ex991.htm">Supplement to the Management Information Circular Dated October 20, 2023</a></p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fsd_ex991.htm
<DESCRIPTION>SUPPLEMENT TO THE MANAGEMENT INFORMATION
<TEXT>
<html><head><title>fsd_ex991.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="fsd_ex991img1.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FSD PHARMA INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>199 BAY ST., SUITE 4000 TORONTO, ON, M5L 1A9</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>www.fsdpharma.com</strong><strong> </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR DATED OCTOBER 20, 2023</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>This supplement dated November 15, 2023 (the &#8220;Supplement&#8221;) to the management information circular (the &#8220;Circular&#8221;) of FSD Pharma Inc. (the &#8220;Corporation&#8221; or &#8220;FSD Pharma&#8221;) dated October 20, 2023 (the &#8220;Circular&#8221;) is furnished in connection with the solicitation of proxies by management of FSD Pharma for use at the special meeting (the &#8220;Meeting&#8221;) of FSD Pharma Securityholders to be held on November 20, 2023, at the hour of 1:00 p.m. (Toronto time), through the AGM Connect meeting platform at www.agmconnect.com/fsdpharma2023, for the purposes set forth in the Circular and the Notice of Meeting accompanying the Circular.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unless the context otherwise requires, capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Circular.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PURPOSE</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The purpose of this Supplement is to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">provide FSD Pharma Securityholders with disclosure concerning certain restrictions on resale that will apply to the Celly Nu Shares that are proposed to be distributed to the FSD Pharma Securityholders pursuant to the Plan of Arrangement; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">notify FSD Pharma Securityholders that FSD Pharma will now accept proxies received prior to 5:00 p.m. (Toronto time) on Friday, November 17, 2023, in order to provide FSD Pharma Securityholders with additional time to consider how they will vote their respective FSD Pharma Securities.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em></em></strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Restrictions on Resale</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FSD Pharma and Celly Nu have agreed that the Celly Nu Shares that will be distributed to the FSD Pharma Securityholders pursuant to the Plan of Arrangement will be subject to restrictions on transfer, such that none of the Celly Nu Shares may be transferred until May 31, 2024, provided that, Celly Nu may, in its sole discretion, waive such restrictions, in whole or in part.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Extension to Proxy Deadline</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Chair of the Meeting has the discretion to accept proxies received less than 48 hours prior to the Meeting and, to ensure that FSD Pharma Securityholders have sufficient time to vote, FSD Pharma will now accept proxies received prior to 5:00 p.m. (Toronto time) on Friday, November 17, 2023. The form of proxy previously sent to FSD Pharma Securityholders remains valid for use at the Meeting, and no new form of proxy is included with this Supplement. FSD Pharma Securityholders who have already submitted a proxy or voting instruction form and do not wish to change their vote, do not need to take any further action with respect to the Meeting. FSD Pharma Securityholders who wish to change their vote should refer to &#8220;Appointment of Proxyholders and Revocation of Proxies&#8221; in the Circular.</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>fsd_ex991img1.jpg
<TEXT>
begin 644 fsd_ex991img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !N -,# 2(  A$! Q$!_\0
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M [6O!_&G[+W@/QUXUU+Q7JVJ:Q%>Z@X>1+>6-4!"A> 4)Z =Z]XIK8X[9XH
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M)FL;Q)H-GXH\/3Z+J#R);3M&S&)L-\CJXY^JB@#F?[5^+F>/!_ATC_L,2?\
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BK?4-(F:6WG@;:Q5EP\3?WD88R/4 ]JW^]  >M%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
